Search

Displaying results 1421 - 1430 of 6831 in total
  1. Drug

    Potassium gluconate

    go.drugbank.com/drugs/DB13620
    Approved

    Potassium gluconate is believed to be more palatable and non-acidifying than potassium chloride (KCl) [L2658]. … In dietary supplements, potassium is often present as potassium chloride, but many other forms—including potassium citrate, phosphate, aspartate, bicarbonate, and **gluconate**—are also used [L2652].

  2. Drug

    Allopurinol

    go.drugbank.com/drugs/DB00437
    ApprovedInvestigational

    Allopurinol is a xanthine oxidase enzyme inhibitor that is considered to be one of the most effective drugs used to decrease urate levels and is frequently used in the treatment of chronic gout [A36705 … It was initially approved by the FDA in 1966 [L5674] and is now formulated by several manufacturers [L5677].

  3. Drug

    Carbopol 974P

    go.drugbank.com/drugs/DB05384
    ApprovedWithdrawn

    The compound, known as BufferGel, was in advanced clinical trials for its ability to prevent pregnancy, but was discontinued. … It was under development by ReProtect LLC. It is a gel that may help both block the spread of sexually transmitted diseases and reduce unwanted pregnancies.

  4. Drug

    Tirzepatide

    go.drugbank.com/drugs/DB15171
    ApprovedInvestigational

    [A246260] Tirzepatide comprises a 39 amino acid linear synthetic peptide conjugated to a C20 fatty diacid moiety. … [L48766] On September 15, 2022, tirzepatide was also approved by the European Commission.[L44386]. On November 02, 2023, tirzepatide was also approved by the Health Canada [L52800]

  5. Drug

    Bioallethrin

    go.drugbank.com/drugs/DB13746
    ApprovedWithdrawn

    A mixture of the two same stereoisomers, but in an approximate ratio of R:S in 1:3, is called esbiothrin. … It is claimed to have low mammalian toxicity.

  6. Drug

    Atogepant

    go.drugbank.com/drugs/DB16098
    ApprovedInvestigational

    [L38814] While its approval was predated by two other members of the same drug family, namely [ubrogepant] and [rimegepant], these agents are indicated only for abortive migraine therapy - atogepant is … It was developed by AbbVie and received FDA approval under the brand name Qulipta in September 2021.

  7. Drug

    Ozenoxacin

    go.drugbank.com/drugs/DB12924
    Approved

    To date, ozenoxacin has been used in trials studying the treatment of impetigo. As of December 11, 2017 the FDA approved Ferrer Internacional S.A.' … s Xepi (ozenoxacin 1%) as a topically applied cream indicated for the treatment of impetigo caused by *Staphylococccus aureus* or *Streptococcus pyogenes* in adult and pediatric patients 2 months of age

  8. Drug

    Mirtazapine

    go.drugbank.com/drugs/DB00370
    ApprovedInvestigational

    [A178144,L6160] In addition to its beneficial effects in depression, mirtazapine has been reported to be efficacious in the off-label management of various other conditions. … [A177946] This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: Co Mirtazapine
  9. Drug

    Mebanazine

    go.drugbank.com/drugs/DB09248
    ApprovedWithdrawn

    It was used in the past as an antidepressant in the 1960s, but has since been discontinued because of its hepatotoxic potential. … Mebanazine, also known as _Actomol_, is a monoamine oxidase inhibitor (MAOI) belonging to the _hydrazine_ class of chemicals.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  10. Drug

    Glasdegib

    go.drugbank.com/drugs/DB11978
    ApprovedInvestigational

    [A40310] The great lipophilicity of this group of compounds brought interest to further modification. … [A40310] Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML).